Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palonosetron and Aprepitant for CINV in ASCT
NCT00600353Phase 2Completed
- Sponsor
- University of Kansas Medical Center
- Start
- Oct 2007
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of palonosetron, aprepitant in chemotherapy-induced nausea and vomiting (CINV), sponsored by University of Kansas Medical Center. Started Oct 2007; status: completed.
02
Drugs
palonosetronaprepitant
03
Conditions
chemotherapy-induced nausea and vomiting (CINV)
Beyond the preview
Go deeper on NCT00600353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00600353.